Pathkind Diagnostics Revenue and Competitors
Claim your profile
Estimated Revenue & Valuation
- Pathkind Diagnostics's estimated annual revenue is currently $357.6M per year.
- Pathkind Diagnostics's estimated revenue per employee is $457,274
Employee Data
- Pathkind Diagnostics has 782 Employees.
- Pathkind Diagnostics grew their employee count by 31% last year.
Pathkind Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $285M | 623 | 2% | N/A | N/A |
#2 | $5.3M | 23 | -4% | N/A | N/A |
#3 | $25.9M | 79 | -14% | N/A | N/A |
#4 | $31.3M | 96 | 3% | N/A | N/A |
#5 | $8.9M | 34 | 0% | N/A | N/A |
#6 | $24.3M | 74 | 4% | N/A | N/A |
#7 | $150.2M | 368 | 7% | N/A | N/A |
#8 | $25.9M | 79 | 27% | N/A | N/A |
#9 | $76.6M | 213 | 19% | N/A | N/A |
#10 | $8.4M | 39 | 8% | $57.4M | N/A |
What Is Pathkind Diagnostics?
To be a Trusted Brand having Pan-India footprint, making Superior Quality Diagnostics Services Accessible to the masses at Affordable Price through Innovative means.
keywords:N/AN/A
Total Funding
782
Number of Employees
$357.6M
Revenue (est)
31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pathkind Diagnostics News
2017-08-29 - ADK Fortune bags creative mandate for Pathkind Diagnostics
Pathkind Diagnostics, a pan-India network of labs and collection centres, announced the appointment of ADK Fortune Communications as its ...
2017-03-29 - Mankind Pharma mulls to invest Rs 305-crore in Pathkind Diagnostics
"We are foraying into diagnostics space with new venture Pathkind Diagnostics. In the coming 4 years, the company has a plan to invest Rs 305 ...
2017-03-24 - Mankind Pharma set to foray into diagnostics with Pathkind
Delhi-based pharmaceutical company Mankind Pharma, known for its contraceptive products, is all set to make its foray into the diagnostic ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $371.4M | 782 | N/A | N/A |
#2 | $238.4M | 782 | 3% | N/A |
#3 | $238.6M | 783 | N/A | N/A |
#4 | $239.4M | 785 | 10% | N/A |
#5 | $274.6M | 785 | -5% | N/A |